Evidence from other studies suggests that this cytokine in particular may be targets for treatment in HF patients, with a post-hoc analysis of CANTOS demonstrating that the IL-1β inhibitor canakinumab caused a dose-dependent reduction in subsequent HF hospitalisation in individuals with high levels of inflammation at randomisation [28]. Here, IL1B is linked to hydrops fetalis.